MEDI0618, Placebo to match MEDI0618
D7060C00003(M26-031)
Phase 2 small_molecule active
Quick answer
MEDI0618, Placebo to match MEDI0618 for Migraine is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Migraine
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active